Aimmune Therapeutics, Inc. (NASDAQ: AIMT)
Aimmune Therapeutics, Inc. (AIMT), a clinical-stage biopharmaceutical company yesterday reported their third quarter 2106 financial results. Aimmune reported third quarter earnings of a loss of $0.53 per share. Aimmune reported a third quarter loss of $221.1 million.
Aimmune Therapeutics, Inc. CEO’s Comments
“These are exciting times at Aimmune with the recently announced equity investment by Nestlé Health Science, completion of North American enrollment in the Phase 3 PALISADE trial of AR101, and progress on plans for RAMSES, a real-world experience trial of AR101,” said Aimmune CEO Stephen Dilly, M.B.B.S., Ph.D. “Our research and development expenses were significantly higher this quarter as a result of exceeding our enrollment target in PALISADE in North America and a lower patient dropout rate than initially projected. We expect to complete European enrollment in PALISADE by year-end, keeping us on track for top-line data in the fourth quarter of 2017. In addition, we look forward to initiating RAMSES in early 2017 and beginning our collaboration with Nestlé Health Science. Their investment will put us in a strong cash position of approximately $300 million and enable important additional pipeline advancement activities beyond AR101 for peanut allergy. We look forward to sharing additional details on our development plans and progress in the coming months.” Business Wire
AIMT Technical Analysis
AIMT opened trading yesterday at $25.80 which was up from the previous day’s trading close of $25.50. AIMT closed trading yesterday at $26.70 and crashed down after market to $24.99, equivalent to a 6% decrease from the closing price. Taking a look at the daily chart we can see that the last time AIMT traded below these levels we have to go back to November 10th when it traded at lows of $24.52. Taking a closer look at the daily chart we can see that before the spike down AIMT had been in an overall upward trend dating back to July 7th when it traded at 10.26. AIMT has a float of 23.4 million shares and traded 2.66 times the normal daily trading volume on Monday. For trading purposes, I would like to see AIMT open trading on Tuesday below $25.50 and if it does I would be looking to take a short position at the bell. My stop loss would be $0.25 from my entry position fearing anything more than that and the stock would start to fill in the gap down. My friend Ross over at Warrior Trading is applying his Day Trading Strategies to these types of stocks.
Company Profile
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of desensitization treatments for peanut and other food allergies. Its Characterized Oral Desensitization Immunotherapy includes AR101, a product in Phase 3 registration trial for the treatment of peanut allergy in children and adults. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. The company was founded in 2011 and is headquartered in Brisbane, California. Yahoo Finance
